EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Jiyun Lee, Sehhoon Park, Hyun Ae Jung iD, Se-Hoon Lee, Seyoung Seo, Sung-Bae Kim, Ji-Won Kim, Keun-Wook Lee, Eun Joo Kang, Ju Won Kim, Yoon Ji Choi, Byoung-Yong Shim und 7 weitere

Cancer · 2023-10 · 129 (19) · 2966-2974

DOI: 10.1002/cncr.34892 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 28.05.2023. Verfasst von Jiyun Lee und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Ductal, Breast Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. The high positivity rate for human epidermal growth factor receptor 2 (HER2) led to an investigation of the efficacy of HER2‐targeted agents. Docetaxel‐PM (polymeric micelle) is a low‐molecular‐weight, nontoxic, biodegradable, and docetaxel‐loaded micellar formulation. Trastuzumab‐pkrb is a biosimilar to trastuzumab.

Methods

This was a multicenter, single‐arm, open‐label phase 2 study. Patients with HER2‐positive (immunohistochemistry [IHC] score of ≥2+ and/or HER2/chromosome enumeration probe 17 [CEP17] ratio of ≥2.0) advanced SDCs were enrolled. Patients received docetaxel‐PM (75 mg/m 2 ) and trastuzumab‐pkrb (8 mg/kg in the first cycle and 6 mg/kg in subsequent cycles) every 3 weeks. Primary end point was objective response rate (ORR).

Results

A total of 43 patients were enrolled. The best objective responses were partial response in 30 (69.8%) patients and stable disease in 10 (23.3%) patients, leading to an ORR of 69.8% (95% confidence interval [CI], 53.9–82.8) and a disease control rate of 93.0% (80.9–98.5). Median progression‐free survival, duration of response, and overall survival were 7.9 (6.3–9.5), 6.7 (5.1–8.4), and 23.3 (19.9–26.7) months, respectively. Patients with HER2 IHC score of 3+ or HER2/CEP17 ratio ≥2.0 demonstrated better efficacies compared to those with HER2 IHC score of 2+. Thirty‐eight (88.4%) patients experienced treatment‐related adverse events (TRAE). Because of TRAE, nine (20.9%), 14 (32.6%), and 19 (44.2%) patients required temporary discontinuation, permanent discontinuation, or dose reduction, respectively.

Conclusions

The combination of docetaxel‐PM and trastuzumab‐pkrb demonstrated promising antitumor activity with a manageable toxicity profile in HER2‐positive advanced SDC. Plain Language Summary Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. SDC shares morphological and histological similarities with invasive ductal carcinoma of breast, which led to an investigation of hormonal receptor and human epidermal growth factor receptor 2 (HER2)/neu expression status in SDC. In this study, patients with HER2‐positive SDC were enrolled and treated with combination of docetaxel‐polymeric micelle and trastuzumab‐pkrb. Promising antitumor activities were shown with objective response rate of 69.8%, disease control rate of 93.0%, median progression‐free survival of 7.9 months, median duration of response of 6.7 months, and median overall survival of 23.3 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, DuctalBreast NeoplasmsHumansFemaleDocetaxelMicellesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsTrastuzumabErb-b2 Receptor Tyrosine KinasesSalivary Glands

Stichwörter der Autor:innen

HER2docetaxel-PMhead and neck cancerssalivary duct carcinomatrastuzumab-pkrb

Substanzen

DocetaxelMicellesAntibodies, Monoclonal, HumanizedTrastuzumabErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
  • Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Medical Oncology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.

ORCID-Profile: Hyun Ae Jung, Myung-Ju Ahn

Zitieren

APA

Lee, J., Park, S., Jung, H. A., Lee, S. H., Seo, S., Kim, S. B., Kim, J. W., Lee, K. W., Kang, E. J., Kim, J. W., Choi, Y. J., Shim, B. Y., An, H. J., Park, L. C., Shin, S. H., Kim, J. J., Oh, S. Y., Kim, M. K., & Ahn, M. J. (2023). A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Cancer, 129(19), 2966-2974. https://doi.org/10.1002/cncr.34892

Vancouver

Lee J, Park S, Jung HA, Lee SH, Seo S, Kim SB, et al. A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Cancer. 2023;129(19):2966-2974. doi:10.1002/cncr.34892

BibTeX
@article{Lee2023,
  author = {Lee, Jiyun and Park, Sehhoon and Jung, Hyun Ae and Lee, Se-Hoon and Seo, Seyoung and Kim, Sung-Bae and Kim, Ji-Won and Lee, Keun-Wook and Kang, Eun Joo and Kim, Ju Won and Choi, Yoon Ji and Shim, Byoung-Yong and An, Ho-Jung and Park, Lee Chun and Shin, Seong Hoon and Kim, Jae-Joon and Oh, So Yeon and Kim, Min Kyoung and Ahn, Myung-Ju},
  title = {A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {19},
  pages = {2966--2974},
  doi = {10.1002/cncr.34892}
}
Kostenlos starten →